

# BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI – 400 001.

Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

14<sup>th</sup> February, 2019

To  
Department of Corporate Service  
Corporate Relation Department  
**Bombay Stock Exchange Ltd.,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**BSE Script Code: 524516**

**Subject : Outcome of Board Meeting held today on 14<sup>th</sup> February, 2019**

**Ref. : Regulation 30 & 33 of the SEBI (LODR) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its meeting held today, inter alia, transacted and approved the following business:

1. Un-audited Financial Results of the Company for the Quarter and Nine Months ended 31st December, 2018 along with Statutory Auditors' Limited Review Report.

The Board Meeting was concluded at 7:30 PM

You are hereby requested to take the same on records.

Thanking You

Yours Faithfully  
For **BACIL PHARMA LIMITED**

  
Prakash Shah  
Director



Enclosure: As above

# BACIL PHARMA LIMITED

CIN:L24200MH1987PLC043427

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2018

(Amount in Lacs)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	-	-	-	-	-	-
	Other income	1.64	1.54	5.19	4.70	25.97	27.41
	<b>Total revenue</b>	<b>1.64</b>	<b>1.54</b>	<b>5.19</b>	<b>4.70</b>	<b>25.97</b>	<b>27.41</b>
2	<b>Expenses</b>						
	Employee benefits expense	2.57	1.72	2.11	6.65	5.07	12.61
	Depreciation and amortization expense	0.21	0.22	0.23	0.65	0.45	1.02
	Other expenses	7.75	9.60	5.76	26.55	17.00	19.44
	<b>Total expenses</b>	<b>10.54</b>	<b>11.54</b>	<b>8.11</b>	<b>33.85</b>	<b>22.52</b>	<b>33.07</b>
3	<b>Profit/(Loss) from exceptional item before tax</b>	<b>(8.90)</b>	<b>(10.00)</b>	<b>(2.92)</b>	<b>(29.15)</b>	<b>3.44</b>	<b>(5.66)</b>
	Exceptional Item	-	-	-	-	-	369.48
4	<b>Profit / (Loss) from ordinary activities before tax</b>	<b>(8.90)</b>	<b>(10.00)</b>	<b>(2.92)</b>	<b>(29.15)</b>	<b>3.44</b>	<b>(375.14)</b>
5	<b>Tax expense:</b>						
	(1) Current tax	-	-	-	-	-	-
	(2) Earlier year's Tax	-	-	-	-	-	-
	(3) Deferred tax	-	-	-	-	-	(0.14)
	<b>Total tax expense</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(0.14)</b>
6	<b>Profit/(Loss) from ordinary activities after tax</b>	<b>(8.90)</b>	<b>(10.00)</b>	<b>(2.92)</b>	<b>(29.15)</b>	<b>3.44</b>	<b>(375.00)</b>
7	<b>Other Comprehensive Income (OCI)</b>						
	<u>Item that will not be reclassified to profit or loss</u>						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	13.58	(5.19)	7.99	(8.47)	(6.96)	(56.32)
	Income tax relating to these items	(3.36)	2.94	(2.06)	3.92	2.56	11.48
	<b>Total Other Comprehensive Income (OCI)</b>	<b>10.21</b>	<b>(2.25)</b>	<b>5.93</b>	<b>(4.55)</b>	<b>(4.40)</b>	<b>(44.84)</b>
	<b>Profit/(Loss) for the Period</b>	<b>1.31</b>	<b>(12.25)</b>	<b>3.01</b>	<b>(33.71)</b>	<b>(0.96)</b>	<b>(419.84)</b>
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	589.00	589.00	589.00	589.00	589.00	589.00
8	<b>Earning Per Share (EPS) (Not annualised)</b>						
	(1) Basic	(0.15)	(0.17)	(0.05)	(0.49)	0.06	(6.37)
	(2) Diluted	(0.15)	(0.17)	(0.05)	(0.49)	0.06	(6.37)

**Notes:**

1. The above Unaudited result have been reviewed by the Audit Committee and approved by the Board of Director at its meeting held on 14th February 2019
2. The statutory Auditors of the company have carried out the limited review.
3. The company has adopted Indian Accounting Standard (Ind AS) effective from 1st April' 2017 (Transition date being 1st April' 2016) and accordingly the financial results for the quarter ended 31st December' 2018 have been prepared in accordance with the recognition and measurement principles laid down in Ind AS-34 Interim Financial Reporting prescribed under section 133 of the Companies Act' 2013.
4. No provisions of Deferred Tax Assets has been recognized in the current quarter as well as in earlier periods, It will be recognised annually.
5. Previous quarter figures have been regrouped /reclassified wherever necessary, to make them comparable.
6. The Company has no Separate Reportable Segment.

For BACIL PHARMA LIMITED

Prakash Shah  
Director  
DIN: 01136800  
Place: Mumbai  
Dated: 14/02/2019





# Laxmikant Kabra & Co.

## Chartered Accountants

### INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

#### TO THE BOARD OF DIRECTORS OF BACIL PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Bacil Pharma Limited** ("the Company") for the quarter and nine months ended December 31, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Read with SEBI circular number CIR/CFD/FAC/62/2016 dated 5 July 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI ( Listing Obligation And Disclosure Requirements) Regulation, 2015 read with SEBI circular number CIR/CFD/FAC/62/2016 dated 5 July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

*For Laxmikant Kabra & Co.*  
*Chartered Accountants*  
*Firm Reg. No. 117183W*

*L.K. Kabra*

**CA Laxmikant Kabra**  
*(Partner)*  
**Membership No.101839**



*Place: Thane,*  
*Date: 14<sup>th</sup> February, 2019*